Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

May 31, 2021 Auto Bot Beovu, Clinical Trials, Novartis, P-III 0

Shots:

  • The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg, q4w) vs aflibercept (2 mg, q4w) following the loading phase in patients with wet AMD who have persistent retinal fluid despite anti-VEGF therapy
  • Results: met its 1EPs i.e. non-inferiority in mean change in BCVA from baseline and superiority on 2EPs @ 1 yrs. Beovu (6mg, q4w) was associated with higher rates of IOI (9.3% vs 4.5%) which includes RV (0.8% vs 0.0%) & RO (2.0% vs 0.0%), overall rate of vision (4.8% vs 1.7%)
  • Novartis has decided on early termination of the RAPTOR & RAVEN studies, which assessed the efficacy & safety of Beovu in RVO, and included 6 initial monthly injections

Click here to­ read full press release/ article | Ref: Novartis | Image: BioSpace

The post Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration first appeared on PharmaShots.